Comprender la promoción farmacéutica y responder a ella - Multiple ...

42 | Comprender la promoción farmacéutica y responder a ella - una guía prácticaOrlowski JP, Wateska L (1992). The effects of pharmaceutical firm enticements on physician prescribing patterns.Chest, 102:270-273.Prochaska JO, DiClemente CC (1983). Stages and processes of self-change of smoking: toward an integrativemodel of change. Journal of Consulting and Clinical Psychology, 51:390-395.Prosser H, Almond S, Walley T (2003). Influences on GPs' decisions to prescribe new drugs - the importance ofwho says what. Family Practice 20(1): 61-68.Robinson P, Heywood P (2000). What do GPs need to know? The use of knowledge in general practice consultations.British Journal of General Practice, 50:56-9.Ross JS, Lackner JE, Lurie P et al. (2007). Pharmaceutical company payments to physicians: early experiences withdisclosure laws in Vermont and Minnesota. Journal of the American Medical Association, Mar 21:297(11):1216-23.Roughead EE, Harvey KJ, Gilbert AL (1998). Commercial detailing techniques used by pharmaceutical representativesto influence prescribing. Australia and New Zealand Journal of Medicine, junio 28(3):306-10.Sagarin BJ, Cialdini RB, Rice WE et al. (2002). Dispelling the illusion of invulnerability: the motivations andmechanisms of resistance to persuasion. Journal of Personality and Social Psychology, septiembre, 83(3):526-41.Sahlins M, Stone Age Economics. Chicago: Aldine, 1972; passim.Schafer A (2004). Biomedical conflicts of interest: a defence of the sequestration thesis. Journal of Medical Ethics2004: 30: 8-24, p. 21.Shaughnessy AF, Slawson DC, Bennett JH (1994). Separating the wheat from the chaff: identifying fallacies inpharmaceutical promotion. Journal of General Internal Medicine, octubre 9(10):563-8.Steinman MA, Shlipak MG, McPhee SJ (2001). Of principles and pens: attitudes and practices of medicine housestafftoward pharmaceutical industry promotions. American Journal of Medicine, mayo, 110(7):551-7.Steinman MA, Bero LA, Chren MM et al. (2006). The promotion of gabapentin: an analysis of internal industrydocuments. Annals of Internal Medicine. 145:284-293.Therapeutics Initiative (2002). Do single stereoisomer drugs provide good value? Therapeutics Letter, 45, junio -septiembre (http://www.ti.ubc.ca/pages/letter45.htm, se tuvo acceso el 17 de abril de 2009).Wolfe SM (1996). Why do American drug companies spend more than $12 billion a year pushing drugs? Is iteducation or promotion? Characteristics of materials distributed by drug companies: Four points of view. Journalof General Internal Medicine, Oct;11(10):637-9.Zaltman G (2003). How customers think: essential insights into the mind of the market. Boston: Harvard BusinessSchool Press.Zipkin DA, Steinman MA (2005). Interactions between pharmaceutical representatives and doctors in training: athematic review. Journal of General Internal Medicine, junio 13, 20(8):777-86.